Mylan ( Mylan )


Mylan's picture

Mylan is one of the world’s leading generics and specialty pharmaceutical companies, providing products to customers in approximately 150 countries and territories. The company maintains one of the industry’s broadest and highest quality product portfolios, which is regularly bolstered by an innovative and robust product pipeline. With a workforce of more than 18,000, Mylan has attained leading positions in key international markets through its wide array of dosage forms and delivery systems, significant manufacturing capacity, global commercial scale and a committed focus on quality and customer service.

Mylan press release, blog etc

10/05/2017 - 12:39 Mylan, in Partnership with Synthon, Receives Marketing Authorization Approval in Europe for First Generic for Copaxone 40 mg/mL
10/04/2017 - 04:16 Mylan Provides Support for U.S. Disaster-Relief Efforts
10/03/2017 - 18:55 Mylan Confirms U.S. Launch of First Generic for Copaxone 40 mg/mL 3-Times-a-Week and Generic for Copaxone 20 mg/mL Once-Daily
10/03/2017 - 16:44 Mylan Announces U.S. FDA Approval of First Generic for Copaxone 40 mg/mL 3-Times-a-Week and May Be Eligible for 180-Day Exclusivity
10/02/2017 - 15:09 Mylan Launches Generic Cancidas for Injection
09/29/2017 - 12:53 Mylan Launches Generic Gleevec Tablets
09/14/2017 - 10:06 Mylan Expands Women's Healthcare Portfolio with Launch of Generic Minastrin 24 FE Tablets
09/13/2017 - 05:45 Mylan Names Dennis Zeleny as Chief Human Relations Officer
09/08/2017 - 12:37 Mylan Statement on Warning Letter Issued to Pfizers EpiPen Auto-Injector Manufacturing Site
08/24/2017 - 03:31 Otsuka and Mylan Announce License Agreement to Commercialize Delamanid (Deltyba) for Multidrug-Resistant Tuberculosis (MDR-TB) in High-Burden Countries
08/17/2017 - 08:36 Mylan Finalizes Settlement Agreement on Medicaid Rebate Classification for EpiPen Auto-Injector
08/10/2017 - 04:36 Mylan Advances Access in the Fight Against HIV with the Launch of Three Generic Antiretroviral Medicines in Canada
08/07/2017 - 21:51 Mylan Launches Avonza in India
08/07/2017 - 03:54 Mylan Receives Tentative Approval for "TLD" Under PEPFAR
07/27/2017 - 02:54 Mylan Launches MyHep All in India
07/26/2017 - 10:38 Mylan Receives WHO Prequalification for Generic Sovaldi
07/19/2017 - 17:04 Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD)
07/13/2017 - 15:49 FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Biocon's Proposed Biosimilar Trastuzumab